1. Health technology

  2. •

    Pharmaceuticals: major
Sandoz Group AG

Sandoz Group AG

84.03
USD
+3.63
(+4.52%)
31.78BMarket Cap
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
19.95
19.52
21.9
20.46
- -
Basic EPS, GAAP
1.82
0.15
- -
1.68
- -
Free Cash Flow per Basic Share
1.71
-0.51
0.13
1.49
- -
Dividend per Share
- -
- -
0.45
0.58
- -
Book Value per Share
18.76
16.91
17.19
17.18
17.18
Tangible Book Value per Share
-0.31
-0.99
-1.64
-0.91
-0.91
Basic Weighted Avg Shares
431
430
430
432
432
Sales/Revenue/Turnover
8,599
8,393
9,420
8,841
- -
Operating Margin (%)
13.31
3.76
2.96
12.77
- -
Depreciation Expense
455
442
455
432
- -
Net Income, GAAP
784
65
- -
724
- -
Effective Tax Rate (%)
22.87
38.46
- -
24.28
- -
Profit Margin (%)
9.11
0.77
- -
8.19
- -
Working Capital
-1,791
1,576
1,355
1,006
1,006
LT Debt
109
3,558
4,233
3,970
3,970
Total Equity
8,095
7,279
7,406
7,436
7,436
Return on Invested Capital (%)
- -
1.9
- -
6.86
- -
Return on Capital (%)
- -
1.71
- -
7.21
- -
Return on Common Equity (%)
- -
0.84
- -
9.76
- -

Capital Structure

CHF

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
170
154
533
LT Borrowings
3,982
4,122
3,720
LT Finance Leases
250
236
250
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
431
431
433
Market Capitalization
15,842
18,262
25,183

Working Capital

CHF

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
7,077
6,637
6,470
Cash, Cash Equivalents & STI
1,080
1,101
1,378
Accounts Receivable, Net
2,000
1,834
1,987
Inventories
2,540
2,439
2,254
Total Current Liabilities
5,722
5,134
5,463
Payables & Accruals
- -
- -
- -
ST Debt
170
154
533
Deferred Revenue
- -
- -
- -

Growth Rates

CHF

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
0.41%
Free Cash Flow
- -
- -
1,079.18%
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
-6.15%
Total Cash Common Dividend
- -
- -
27.97%

Quarterly Revenue

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
8,393
2024
- -
- -
- -
- -
9,420
2025
- -
- -
- -
- -
8,841

Quarterly Earnings Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.15
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
1.68

Quarterly Dividends Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
0.45
2025
- -
- -
- -
- -
0.58

Company Description

Company Profile APIChatGPT
Address
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business

Company News

Company News APIChatGPT

  • zacks.com

    NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now?

  • zacks.com

    GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?

  • prnewswire.com

    mAbxience and Sandoz Sign a Collaboration Agreement to Advance Biosimilar Access Worldwide

  • wsj.com

    Sandoz Gets Canada Approval for Generic Version of Ozempic

  • seekingalpha.com

    Sandoz Group AG (SDZNY) Analyst/Investor Day Transcript

  • zacks.com

    GRFS or SDZNY: Which Is the Better Value Stock Right Now?

  • reuters.com

    Switzerland's Sandoz pivots to biosimilars, expects rapid mid-term growth

  • zacks.com

    3 Generic Drug Stocks to Watch Amid Improving Industry Trends

  • prnewswire.com

    Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

  • reuters.com

    Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech

  • seekingalpha.com

    Sandoz Group AG (SDZNY) Q2 2026 Earnings Call Transcript

  • wsj.com

    Sandoz Shares Climb After Biosimilar Sales Drive Growth

  • reuters.com

    Sandoz results narrowly beat sales expectations

  • zacks.com

    UTHR or SDZNY: Which Is the Better Value Stock Right Now?

  • wsj.com

    Sandoz to Pay Around $480 Million to Settle U.S. Antitrust Pricing Litigations

  • reuters.com

    Sandoz agrees $450 mln settlement with 43 US states over antitrust claims

  • reuters.com

    Generic drug sector seeks policy fixes after Trump tariff threat

  • reuters.com

    Generic drugmaker Sandoz to engage with US after Trump tariff threat

  • reuters.com

    FDA set to review Sandoz's generic GLP-1s

  • zacks.com

    3 Generic Drug Stocks to Watch as New Growth Drivers Emerge